Abstract

Cre recombinase is extensively used to engineer the genome of experimental animals. However, its usefulness is still limited by the lack of an efficient temporal control over its activity. We have recently developed a conceptually new approach to regulate Cre recombinase, that we have called Dimerizable Cre or DiCre. It is based on splitting Cre into two inactive moieties and fusing them to FKBP12 (FK506-binding protein) and FRB (binding domain of the FKBP12-rapamycin associated protein), respectively. These latter can be efficiently hetero-dimerized by rapamycin, leading to the reinstatement of Cre activity. We have been able to show, using in vitro approaches, that this ligand-induced dimerization is an efficient way to regulate Cre activity, and presents a low background activity together with a high efficiency of recombination following dimerization. To test the in vivo performance of this system, we have, in the present work, knocked-in DiCre into the Rosa26 locus of mice. To evaluate the performance of the DiCre system, mice have been mated with indicator mice (Z/EG or R26R) and Cre-induced recombination was examined following activation of DiCre by rapamycin during embryonic development or after birth of progenies. No recombination could be observed in the absence of treatment of the animals, indicating a lack of background activity of DiCre in the absence of rapamycin. Postnatal rapamycin treatment (one to five daily injection, 10 mg/kg i.p) induced recombination in a number of different tissues of progenies such as liver, heart, kidney, muscle, etc. On the other hand, recombination was at a very low level following in utero treatment of DiCre×R26R mice. In conclusion, DiCre has indeed the potentiality to be used to establish conditional Cre-deleter mice. An added advantage of this system is that, contrary to other modulatable Cre systems, it offers the possibility of obtaining regulated recombination in a combinatorial manner, i.e. induce recombination at any desired time-point specifically in cells characterized by the simultaneous expression of two different promoters.

Highlights

  • The technology of gene inactivation through homologous recombination has, since its introduction in the late eighties, boosted immensely our understanding of the role of a great number of genes

  • This characterization indicated that these combinations differ in their background activity and/or the level of activity obtained following dimerization

  • As detailed previously [24], Cre59.F2 corresponds to the Nterminal moiety of Cre to which FKBP12 is fused through the flexible linker F2, while Cre60.F2 corresponds to the C-terminal moiety of Cre to which FRB is fused through the same flexible linker F2

Read more

Summary

Introduction

The technology of gene inactivation through homologous recombination has, since its introduction in the late eighties, boosted immensely our understanding of the role of a great number of genes. The modifications induced by the inactivation of a given gene at an early developmental stage (the most extreme modification being the lethality induced by the inactivation) may interfere with, and make often impossible, the evaluation of a possible late role of that gene. The introduction of the Cre/LoxP system has made this approach possible. Cre is a site specific recombinase that catalyzes the excision of a DNA segment flanked by two identical short (34 bp) asymmetric sequences, called LoxP, of same orientation, introduced into the genome by the experimenter. Conditional inactivation has become a real possibility when solutions have been worked out for the in vivo regulation of Cre activity [2,3,4,5]

Objectives
Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call